Bayer and Exscientia Collaborate to Leverage the Potential of Artificial Intelligence in Cardiovascular and Oncology Drug Discovery

BayerBayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners will work on early research projects combining Exscientia's proprietary AI drug discovery platform and drug design know-how with Bayer's data and drug discovery capabilities. They aim to identify and optimize novel lead structures for potential drug candidates to treat cardiovascular and oncological diseases. Exscientia may be eligible to receive up to EUR 240 million, including upfront and research payments, near term and clinical milestones. As part of the agreement, Exscientia may also receive sales royalties. Bayer owns the rights to novel lead structures generated as part of the collaboration.

AI has the potential to accelerate drug discovery and improve the drug development productivity in terms of quality, cost and cycle time. Up to now, it takes 12 to 15 years from early research to marketing approval of a new drug. The collaboration focuses on early stage research by using an AI-based algorithm to predict potential drug molecules. Exscientia's AI-driven drug discovery technology provides novel chemical matter for difficult-to-address targets and could identify novel drug candidates more efficiently through less optimization cycles.

"We are driving forward digital transformation in R&D as we believe that digital technologies such as AI can simplify and speed up the discovery and development of new drugs for patients," said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development. "The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures."

"We're delighted to collaborate with Bayer, a globally recognized pharmaceutical company who has already committed significant investment to treating challenging diseases," said Professor Andrew Hopkins, CEO of Exscientia. "Since our pioneering Nature papers demonstrated the automated design of small-molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners. We’re excited to now work with Bayer researchers to drive this transformational change in key therapeutic areas."

The Pharmaceuticals Business Development & Licensing team of Bayer facilitated this collaboration.

About artificial intelligence at Bayer Pharmaceuticals

Artificial intelligence provides significant opportunities for Bayer's Pharmaceuticals business. Bayer is committed to realizing the potential value associated with big data, advanced analytics, and artificial intelligence, as it continues to explore and leverage them along the value chain. Bayer believes that there are three ways that artificial intelligence could be applied in our business: to strengthen and accelerate innovation, to advance operations and to identify new business opportunities. Such technologies could therefore support Bayer in getting the right treatment to the right patient at the right time, more efficiently and faster than we do today.

About Exscientia

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Most Popular Now

Researchers Capture First Images of Oxyg…

Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful. Hypoxia, or starvation of oxygen, in solid tumors is also thought to be...

VTT Makes New Investments in Digital Hea…

VTT is launching new research activities in the area of digital health as part of the growing wellbeing and health technology ecosystem in Kuopio. The new initiative aims to create...

A New Method of Artificial Intelligence …

Despite the immense progress in the field of AI in recent years, we are still very far from human intelligence. Indeed, if current AI techniques allow to train computer agents...

FDA Informs Health Care Providers, Facil…

Today, the U.S. Food and Drug Administration is issuing a safety communication informing health care providers, facilities and patients about cybersecurity vulnerabilities identified for certain GE Healthcare Clinical Information Central...

eHealthWeek 2020 Croatia - Trusted Infor…

15 - 17 April 2020, Rovinj, Croatia. In its capacity of hosting the upcoming Presidency of the Council of the European Union, the Croatian Ministry of Health is in preparations to...

Siemens Healthineers Presents Solutions …

CT scanners with intelligent user guidance, AI-based software assistants for MRI and a lab system that revolutionizes workflows: Siemens Healthineers is showcasing its products and solutions according to the motto...

NHS IT Chiefs Set the Stage for a Year o…

3 - 4 March 2019, London, United Kingdom. NHS technology leaders are to kick off the second-ever Digital Health Rewired Conference and Exhibition on 3 - 4 March at the Olympia...

PatchAi Startup has Arrived in the Marke…

PatchAi - a startup that offers, thanks to Artificial Intelligence and Machine Learning, an empathic virtual assistant to patients participating in clinical trials - announced that it has closed two...

Digital Health App Medicus AI Earns CE C…

Medicus AI, the Vienna-based health tech company, has received a ​Class I Medical Device CE Mark for its mobile application. The CE certification mark confirms that Medicus AI conforms to...

FDA Authorizes Marketing of First Cardia…

Today, the U.S. Food and Drug Administration authorized marketing of software to assist medical professionals in the acquisition of cardiac ultrasound, or echocardiography, images. The software, called Caption Guidance, is...

Human Body-on-Chip Platform Enables In V…

Drug development is an extremely arduous and costly process, and failure rates in clinical trials that test new drugs for their safety and efficacy in humans remain very high. According...

AI in Drug Discovery Conference 2020

16 - 17 March 2020, London, UK. SMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London. AI-empowered machine learning technologies hold the potential...